34 reports

  • interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12 and cytoprotectant erythropoietin.
  • JAN 09, 2014: NEUMEDICINES TO FEATURE HEMAMAX STUDY RESULTS IN PRESENTATION AT BIOTECH SHOWCASE CONFERENCE

In the same study, ## consecutive days of treatment with Neupogen® (filgrastim or granulocyte colonystimulating factor [G-CSF]) did not provide any survival benefit versus control.

  • Cytokine
  • Therapy
  • United States
  • Product Initiative
  • Neumedicines Inc.
  • Pipeline by Amgen Inc., H1 2016

The company' s key products include Neulasta (pegfilgrastim); Neupogen (filgrastim) indicated for cancer treatment; Enbrel (entanercept) for treating rheumatoid arthritis; Epogen (Erythropoietic Stimulating Agents); Aranesp (darbepoetin alfa) to treat anemia associated with chronic kidn

  • Cytokine
  • Digestive System Disorder
  • United States
  • World
  • Product Initiative

filgrastim German CLL Study Group Amgen Inc ## Jul 1999 ## Sep 2003 ## ## ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Clinical Trial profile. ## Trial Title Trial Identifier

  • Blood Disease
  • Cytokine
  • Leukemia
  • United States
  • World
  • Clinical Trial profile. 141 Trial Title

Filgrastim or Lenograstim or CSF##), Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF##), Interferon Gamma (Immune Interferon or IFNG), Interleukin ## Alpha (IL ## Alpha or Hematopoietin ## or IL##A), Interleukin ##

  • Cytokine
  • Respiratory Treatment
  • World
  • Product Initiative
  • Windtree Therapeutics, Inc.

Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies GDCT## NCT##

  • Cancer
  • Cytokine
  • Lymphoma
  • World
  • Product Initiative

Filgrastim in Promoting Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant GDCT## NCT##, NCI-2012-##; 2008-##; P##CA## Oncology B-Cell Chronic Lymphocytic Leukemia, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma

  • Cell Therapy
  • Clinical Trial
  • Cytokine
  • Leukemia
  • F. Hoffmann-La Roche Ltd.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Filgrastim or Lenograstim or CSF##), Hepatitis A Virus Cellular Receptor ## (Kidney Injury Molecule ## or T Cell Immunoglobulin And Mucin Domain Containing Protein ## or T-Cell Immunoglobulin Mucin Receptor ## or T Cell Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Coll

  • Biological Therapy
  • Cytokine
  • Infectious Disease
  • World
  • Product Initiative

The primary outcome measure of the trial was to determine the safety and tolerability of repeated doses of NOX-A## alone and in combination with filgrastim in healthy subjects.

  • Cytokine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Juventas Therapeutics, Inc.

filgrastim Chuncheon Sacred Heart Hospital ## Jul 2015 ## Apr 2020 ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Official Title Clinical Trial profile. ## Trial Title Official

  • Cytokine
  • Digestive System Disorder
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.

filgrastim University of Texas MD Anderson Cancer Center ## Mar 1998 ## Jul 2008 ## ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Clinical Trial profile. ## Trial Title Official

  • Blood Disease
  • Clinical Trial
  • Cytokine
  • Leukemia
  • Novartis AG

filgrastim Institute of Liver and Biliary Sciences ## Jul 2011 ## Jan 2013 ## ## ## ## Official Title Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Dat

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Hepatitis
  • World
  • Clinical Trial Profile Snapshots

Filgrastim or Lenograstim or CSF##), Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF##), Intercellular Adhesion Molecule ## (Major Group Rhinovirus Receptor or CD## or ICAM##), Interferon Gamma (Immune Interferon

  • Cytokine
  • Respiratory Disease
  • World
  • Product Initiative
  • GlaxoSmithKline plc

filgrastim Chuncheon Sacred Heart Hospital ## Jul 2015 ## Apr 2020 ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) The Mechanism of Action of N-acetylcysteine for Reducing the R

  • Cytokine
  • Digestive System Disorder
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.

filgrastim; methylprednisolone; prednisone Fairview University Medical Center ## Mar 2000 ## ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Actual

  • Chronic Disease
  • Clinical Trial
  • Cytokine
  • Musculoskeletal Disorder
  • GlaxoSmithKline plc

The primary outcome measure of the trial was to determine the safety and tolerability of repeated doses of NOX-A## alone and in combination with filgrastim in healthy subjects.

  • Cytokine
  • Hospital
  • Targeted Therapy
  • Therapy
  • Juventas Therapeutics, Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Filgrastim or Lenograstim or CSF##), Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF##), Intercellular Adhesion Molecule ## (Major Group Rhinovirus Receptor or CD## or ICAM##), Interferon Gamma (Immune Interferon

  • Cytokine
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 1081 Trial Title

Filgrastim or Lenograstim or CSF##), Interleukin ## Receptor (IL##R), Interleukin ## (Cytokine Synthesis Inhibitory Factor or CISF or IL##), Interleukin ## (IL##), Interleukin ## (B Cell Stimulatory Factor ## or BSF## or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon B

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Monoclonal Antibody
  • World
  • Clinical Trial profile. 894 Trial Title

filgrastim; mesna TriStar Health System, Inc. ## Aug 2014 ## Aug 2019 Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date Estimated Compl

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • World
  • AbbVie Inc.

Filgrastim (Aryatinagene) to Neupogen (Amgen) in the Prevention of Neutropenic Complications in Breast Cancer Patients in Pange-azar Hospital of Gorgan Clinical Efficacy of Filgrastim-Aryatinagene GDCT## IRCT##N##, Infectious Disease Febrile Neutropenia, Musculoskele

  • Anti-Infective
  • Blood Disease
  • Cytokine
  • World
  • Eli Lilly & Co.

filgrastim + plerixafor) Proteonomix, Inc.

  • Clinical Trial
  • Cytokine
  • Drug Discovery And Development
  • World
  • Product Initiative
  • Clinical Trial profile. 89 Trial Title

filgrastim Foundation for Liver and Gut Studies University of Geneva ## Sep 2005 ## Aug 2006 ## ## ## ## Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients with Type ## Diabetes Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patien

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Therapy
  • World

filgrastim + plerixafor) Proteonomix Inc Numoda Corp ## Oct 2012 ## Sep 2013 ## ## ## Proteomic Study During Perioperation of Liver Transplantation Proteomic Study During Perioperation of Liver Transplantation GDCT## ChiCTR-PNRC-##, Gastrointestinal Hepatitis B, Liver Cancer, Liver

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Hepatitis Treatment
  • World
  • Clinical Trial profile. 337 Trial Title

Filgrastim or Lenograstim or CSF##), Interleukin ## Beta (IL ## Beta or Catabolin or IL##B), Interleukin ## (Cytokine Synthesis Inhibitory Factor or CISF or IL##), Interleukin ## (B Cell Stimulatory Factor ## or BSF## or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Be

  • Clinical Trial
  • Cytokine
  • Neurology
  • World
  • Teva Pharmaceutical Industries Ltd.

Filgrastim or Lenograstim or CSF##), Immunoglobulin E (IgE), Interleukin ## (Cytokine Synthesis Inhibitory Factor or CISF or IL##), Interleukin ## (IL##), Interleukin ## (IL##), Interleukin ## (T Cell Growth Factor or Aldesleukin or IL##), Interleukin ## (B Cell Stimulatory Factor ## or Binetra

  • Clinical Trial
  • Cytokine
  • Drug Discovery And Development
  • Respiratory Disease
  • World

filgrastim; methylprednisolone; prednisone Fairview University Medical Center ## Mar 2000 ## ## ## Target Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date # of Subjects Planned # of Location(s) # of Investigator(s) Clinical Trial profile. ## Trial

  • Cardiology
  • Clinical Trial
  • Cytokine
  • World
  • XOMA Corporation

filgrastim + plerixafor) Rutgers Biomedical and Health Sciences Proteonomix Inc ## Jan 2013 Use of Immune Globulin Intravenous (Human), ##% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting

  • Clinical Trial
  • Cytokine
  • Renal Disease
  • United States
  • World

filgrastim; thiotepa Ospedale S Raffaele ## Dec 2007 ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Da

  • Clinical Trial
  • Cytokine
  • Neurological Disorder
  • World
  • Biogen Idec Inc.

THE COMPANY' S KEY PRODUCTS INCLUDE NEULASTA (PEGFILGRASTIM); NEUPOGEN (FILGRASTIM) INDICATED FOR CANCER TREATMENT; ENBREL (ENTANERCEPT) FOR TREATING RHEUMATOID ARTHRITIS; EPOGEN (ERYTHROPOIETIC STIMULATING AGENTS); ARANESP (DARBEPOETIN ALFA) TO TREAT ANEMIA ASSOCIATED WITH CHRONIC KIDN

  • Cytokine
  • Therapy
  • United States
  • World
  • Product Initiative

Filgrastim or Lenograstim or CSF##), Interferon Gamma (Immune Interferon or IFNG), Interleukin ## Beta (IL ## Beta or Catabolin or IL##B), Interleukin ## (IL##), Interleukin ## (IL##), Interleukin ## (T Cell Growth Factor or Aldesleukin or IL##), Interleukin ## (B Cell Stimulatory Factor ## or Bine

  • Anti-Infective
  • Cytokine
  • United States
  • World
  • Cystic Fibrosis Foundation Therapeutics, Inc.
  • (FILGRASTIM + PLERIXAFOR) - DRUG PROFILE
  • DORMANT PROJECTS, H1 2016
  • Cytokine
  • R&D
  • Renal Cancer
  • Research And Development
  • BioLineRx Ltd.